ArticleNeurology and therapy2026
Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Adults of Hispanic or Latino Ethnicity: Post Hoc Analysis of Three Randomized, Placebo-Controlled Trials.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis post hoc exploratory analysis evaluated the efficacy and safety of rimegepant 75 mg for the acute treatment of migraine in patients that are Hispanic or Latino (HL), non-HL White (nHLW), and non-HL Black/African American (nHLB/AA).
methodsData were pooled from three multicenter, double-blind, randomized, placebo-controlled, phase 3 trials of rimegepant. Each study comprised a 28-day screening period, treatment phase (up to 45 days), and end of treatment visit within 7 days. Patients treated a single migraine attack of moderate to severe pain intensity during the treatment phase. Co-primary endpoints in the phase 3 trials were pain freedom and freedom from most bothersome symptom (MBS) both at 2 h post dose.
resultsA total of 546 patients that are HL and 2872 patients that are non-HL (nHLW, n = 2215; nHLB/AA, n = 657) were enrolled. Patients that are HL exhibited a trend, but did not achieve statistical significance, with nominal p < 0.05 for pain freedom (PF) (19.9% rimegepant vs. 13.6% placebo, p = 0.051) or freedom from MBS (31.8% rimegepant vs. 31.8% placebo, p = 0.999), both at 2 h post dose. Exploratory analyses showed that patients that are nHLW and patients that are nHLB/AA achieved responses at 0.75-1.5 h and 1-2 h post dose, respectively, for pain relief, PF, and freedom from MBS, and these were maintained through 48 h. Responses for each were delayed in patients that are HL, starting at 3-4 h post dose and maintained through 48 h. Safety outcomes were similar across subgroups.
conclusionRimegepant was effective and safe for the acute treatment of migraine. Co-primary endpoints at 2 h post dose were not met in patients that are HL; exploratory analyses suggest that patients that are HL may experience a 1-2 h delayed response to rimegepant, with a greater proportion of patients that are HL having responded at 24-48 h post treatment.
trial registrationClinicalTrials.gov identifiers: NCT03235479; NCT03237845; NCT03461757.
Indexed as
Identifiers
42839212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.